Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.

Eichenauer DA; Bühnen I; Baues C; Kobe C; Kaul H; Greil R; Moccia A; Zijlstra JM; Her-tenstein B; Topp MS; Just M; von Tresckow B; Eich HT; Fuchs M; Dietlein M; Hartmann S; Engert A; Borchmann P. Blood. 2023 Aug 10;142(6):553-560. doi: 10.1182/blood.2023019939.

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label; single-arm; multicentre; phase 2 study.

Tiede A; Hart C; Knöbl P; Greil R; Oldenburg J; Sachs UJ; Miesbach W; Pfrepper C; Trautmann-Grill K; Holstein K; Pilch J; Möhnle P; Schindler C; Weigt C; Schipp D; May M; Dobbelstein C; Pelzer FJ; Werwitzke S; Klamroth R. Lancet Haematol. 2023 Nov;10(11):e913-e921. doi: 10.1016/S2352-3026(23)00280-6. Epub 2023 Oct 16.

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised; open-label; multicentre; phase 3 trial.

Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ring-hoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A. Lancet Haematol. 2023 Jul;10(7):e495-e509. doi: 10.1016/S2352-3026(23)00089-3. Epub 2023 May 12.

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LU-NAR): a randomised, open-label, pivotal phase 3 study.

Leal T; Kotecha R; Ramlau R; Zhang L; Milanowski J; Cobo M; Roubec J; Petruzelka L; Havel L; Kalmadi S; Ward J; Andric Z; Berghmans T; Gerber DE; Kloecker G; Panikkar R; Aerts J; Delmonte A; Pless M; Greil R; Rolfo C; Akerley W; Eaton M; Iqbal M; Langer C. Lancet Oncol. 2023 Sep;24(9):1002-1017. doi: 10.1016/S1470-2045(23)00344-3.

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.

Leal T; Kotecha R; Ramlau R; Zhang L; Milanowski J; Cobo M; Roubec J; Petruzelka L; Havel L; Kalmadi S; Ward J; Andric Z; Berghmans T; Gerber DE; Kloecker G; Panikkar R; Aerts J; Delmonte A; Pless M; Greil R; Rolfo C; Akerley W; Eaton M; Iqbal M; Langer C. Lancet Oncol. 2023 Sep;24(9):1002-1017. doi: 10.1016/S1470-2045(23)00344-3.

Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial.

Ferdinandus, J; Müller, H; Damaschin, C; Jacob, AS; Meissner, J; Krasniqi, F; Mey, U; Schöndube, D; Thiemer, J; Mathas, S; Zijlstra, J; Greil, R; Feu-ring-Buske, M; Markova, J; Rüffer, JU; Kobe, C; Eich, HT; Baues, C; Fuchs, M; Borchmann, P; Behringer, K. Ann Oncol. 2023 Dec 5:S0923-7534(23)05102-5. doi: 10.1016/j.annonc.2023.11.014. Online ahead of print.

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

Fuchs, M; Jacob, AS; Kaul, H; Kobe, C; Kuhnert, G; Pabst, T; Greil, R; Brö-ckelmann, PJ; Topp, MS; Just, M; Hertenstein, B; Soekler, M; Vogelhuber, M; Zijlstra, JM; Keller, UB; Krause, SW; Dührsen, U; Meissner ,J; Viardot, A; Eich, HT; Baues, C; Diehl, V; Rosenwald, A; Buehnen, I; von Tresckow, B; Dietlein, M; Borchmann, P; Engert, A; Eichenauer, DA. Leukemia. 2024 Jan;38(1):160-167. doi: 10.1038/s41375-023-02064-y. E-pub 2023 Oct 16.

Interim analysis of ELEANOR (n=200): a multi-national; prospective; non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib.

Bartsch, R; Harbeck, N; Wrobel, D; Zaiss, M; Terhaag, J; Guth, D; Distelrath, A; Wuerstlein, R; Zahn, MO; Luftner, D; Schwitter, M; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinkothe, T; Gorray, M; Breitenstein, U. The Breast 62S1 (2023) S20–S21.

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer.

Bartsch, R; Rinnerthaler, G; Petru, E; Egle, D; Gnant, M; Balic, M; Sliwa, T; Singer, C. Wien Klin Wochenschr. 2023 Sep 8. doi: 10.1007/s00508-023-02254-9. Online ahead of print.

Position paper on CDK4/6 inhibitors in early breast cancer.

Gnant, M; Singer, CF; Rinnerthaler, G; Pfeiler, G; Egle, D; Balic, M; Bartsch, R. memo 16, 135–144 (2023). https://doi.org/10.1007/s12254-023-00878-1.